IceCure Gains Key ASBrS Backing for ProSense Cryoablation in Low-Risk Breast Cancer

Icecure Medical ( (ICCM) ) has issued an announcement.

On March 9, 2026, IceCure Medical announced that the American Society of Breast Surgeons’ updated 2026 Resource Guide now recommends cryoablation as an option for biologically low‑risk, early‑stage breast cancer in carefully selected patients. The guidance builds on ProSense®’s October 2025 FDA marketing clearance for treating low‑risk breast cancer in women aged 70 and over, making ProSense® the first and only FDA‑cleared device for breast cancer treatment.

The ASBrS guide underscores cryoablation’s role in breast‑conserving, minimally invasive care, recognizing it as an FDA‑approved alternative to surgery for older patients with low‑risk tumors and as a validated, cosmetically favorable approach for benign fibroadenomas. IceCure said the updated professional guidance, together with existing reimbursement coding, is expected to support broader clinical adoption, increased system placements and higher procedure volumes across an addressable U.S. breast cryoablation population it estimates at about 200,000 women annually.

The most recent analyst rating on (ICCM) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.

Spark’s Take on ICCM Stock

According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.

Icecure Medical’s overall stock score is primarily impacted by its challenging financial performance, with persistent losses and negative cash flows. The technical analysis indicates a bearish trend, and valuation metrics are weak due to unprofitability. However, the positive sentiment from the earnings call, driven by FDA approval and strategic market opportunities, provides some optimism for future growth.

To see Spark’s full report on ICCM stock, click here.

More about Icecure Medical

IceCure Medical Ltd. is an Israel‑based medical device company that develops and markets minimally invasive, liquid‑nitrogen cryoablation systems for destroying benign and malignant tumors. Its flagship ProSense® system, cleared and approved in markets including the U.S., Europe and Asia, targets breast, kidney, bone and lung cancers as an alternative to surgical tumor removal.

ProSense® is designed for relatively short, office‑based procedures that freeze and ablate tumors while aiming to reduce pain, complications and recovery time. The platform, which received U.S. FDA marketing clearance in October 2025 for low‑risk breast cancer in women aged 70 and older, is currently the first and only device authorized in the U.S. for the local treatment of breast cancer.

Average Trading Volume: 269,106

Technical Sentiment Signal: Sell

Current Market Cap: $43.28M

See more data about ICCM stock on TipRanks’ Stock Analysis page.